Karyopharm Therapeutics Inc.
Net SellingKPTI·US·🇺🇸 US
3%buys·97%sales
1,489 transactions$10.3MTotal buys·22 buys
$563.7MTotal sells·758 sells
4040 insiders
Last: Oct 15, 2025
| Date | Insider | Type | Value | |
|---|---|---|---|---|
| Oct 15, 25 | Macomber Lori | Grant | - | |
| Oct 15, 25 | Cheng Sohanya Roshan | Grant | - | |
| Oct 15, 25 | Paulson Richard A. | Grant | - | |
| Oct 15, 25 | Mano Michael | Grant | - | |
| Oct 15, 25 | Poulton Stuart | Grant | - | |
| Oct 15, 25 | Abate Kristin | Grant | - | |
| Oct 1, 25 | Abate Kristin | Sell | $2K | |
| Sep 15, 25 | Abate Kristin | Sell | $148 | |
| Sep 15, 25 | Cheng Sohanya Roshan | Sell | $2K | |
| Sep 15, 25 | Rangwala Reshma | Sell | $3K |
Karyopharm Therapeutics Inc. is seeing coordinated insider selling. 3 insiders sold shares in the last 30 days, with total sell volume of $7K. Overall insider sentiment is bearish (97% sales).
Karyopharm Therapeutics Inc. (KPTI) has recorded 1 489 insider operations, including 22 open-market purchases ($10.3M), 758 sales ($563.7M) and 709 other operations (stock option exercises, grants, tax dispositions, donations). The insider sentiment is bearish (97% sales).
Insider activity at Karyopharm Therapeutics Inc. is sustained, with operations recorded in 10 of the last 12 months — a sign of regular regulatory filings.
Among the most active insiders are Kauffman Michael (CEO), Paulson Richard A. (CEO) & Mason Michael (CFO), with respectively 329, 60, 162 transactions.
Across all 1 489 recorded transactions, the breakdown by type is: sales (758, 51%), exercise (440, 30%), grant (254, 17%), buys (22, 1%), gift (14, 1%).
Data sourced from regulatory filings (SEC Form 4, AMF, BaFin, FI, and other European authorities).
Karyopharm Therapeutics Inc. has recorded 1 489 insider operations in total, including 22 open-market purchases ($10.3M), 758 sales ($563.7M) and 709 other operations (stock option exercises, grants, tax dispositions, donations). The most recent transaction was recorded on October 15, 2025.
Insiders at Karyopharm Therapeutics Inc. are currently net sellers, with 3% purchases and 97% sales across all reported transactions. Total buy volume is $10.3M versus $563.7M in sales, indicating a bearish insider sentiment.
InsiderLens tracks 40 insiders at Karyopharm Therapeutics Inc. (KPTI). Kauffman Michael (CEO, 329 tx), Paulson Richard A. (CEO, 60 tx), Mason Michael (CFO, 162 tx). Data is sourced from mandatory regulatory filings for persons with access to privileged information.
The insider signal for KPTI is bearish, based on a 3% buy ratio across 780 buy and sell transactions reported to financial regulators. Transactions from C-suite executives (CEO, CFO) and board members are generally considered the most informative signals.
Insider trading data for Karyopharm Therapeutics Inc. comes from official regulatory filings: SEC Form 4 (United States), AMF (France), BaFin (Germany), FI (Sweden), and other European financial authorities. These filings are mandatory for directors, officers, and holders of more than 10% of a company's shares. InsiderLens aggregates and normalizes this data for analysis.